Clinical Report: Pitavastatin Lowers Cardiovascular Risk in HIV-Positive Individuals
Overview
The REPRIEVE trial demonstrated that pitavastatin significantly reduces major adverse cardiovascular events (MACE) by 35% in HIV-positive individuals aged 40-75 years with moderate to low cardiovascular risk. This study highlights the importance of statin therapy in this population, particularly given their elevated risk for cardiovascular disease.
Background
People living with HIV (PLWH) face an increased risk of cardiovascular disease (CVD), which is now a leading cause of non-HIV-related mortality. Current guidelines recommend statin therapy for PLWH aged 40-75 years, regardless of lipid levels, particularly for those with a 10-year ASCVD risk of 5% or higher. High-intensity statins are advised for those with a risk > 20%. The REPRIEVE trial provides critical evidence supporting the use of pitavastatin in reducing cardiovascular risk in this vulnerable population.
Data Highlights
Outcome
Pitavastatin
Placebo
HR (95% CI)
MACE (events per 1,000 person-years)
4.81
7.32
0.65 (0.48–0.90)
MI/Cardiac Ischemia
1.40
2.51
0.56 (0.30–1.05)
Stroke/TIA
1.56
2.36
0.66 (0.36–1.21)
Cardiovascular Mortality
0.64
0.85
-
Key Findings
Pitavastatin reduced MACE by 35% compared to placebo.
Participants had a median 10-year ASCVD risk of 4.5%.
Muscle-related symptoms were more frequent in the pitavastatin group (2.3% vs. 1.4%, p<0.05).
Incident diabetes mellitus occurred more often in the pitavastatin group (5.3% vs. 4.0%, p<0.05).
The trial was stopped early for efficacy due to significant findings.
Clinical Implications
The findings support the implementation of statin therapy, specifically pitavastatin, for primary cardiovascular disease prevention in HIV-positive individuals aged 40-75 years. Clinicians should consider the elevated cardiovascular risk in this population and the potential benefits of statin therapy, while monitoring for side effects such as muscle symptoms and diabetes, particularly in the context of ongoing HIV treatment.
Conclusion
The REPRIEVE trial underscores the efficacy of pitavastatin in reducing cardiovascular risk among HIV-positive individuals, reinforcing the need for proactive cardiovascular disease management strategies in this population.
